Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Fig. 3

Percentage of patients reporting scores greater than or equal to normative values on Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), and 36-item Short Form Health Survey (SF-36) at baseline and week 24. LSM between-group differences (sarilumab vs. adalimumab). Nominal p value. BP Bodily pain, GH General health, MCS Mental Component Summary, MH Mental health, PCS Physical Component Summary, PF Physical functioning, q2w Every 2 weeks, RE Role emotional, RP Role physical, SC Subcutaneous, SF Social functioning, VT Vitality

Back to article page